Seattle Genetics (SGEN)
Seattle Genetics Revenues: 48.24M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SGEN Revenues Rankings
| Overall | 35th percentile | 2880 of 4431 |
| Sector | 58th percentile | 195 of 471 in Healthcare |
| Industry | 80th percentile | 26 of 132 in Biotechnology |
SGEN Revenues Range, Past 5 Years
| Minimum | 4.637M | Sep 2007 |
| Maximum | 48.89M | Dec 2011 |
| Average | 17.79M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these SGEN related companies
SGEN News
$SGEN Adcetris accepted by Health Canada for new drug submission. SG looking for drug to be available early 2013.
about 9 days ago by mnobbies
about 9 days ago by mnobbies
Health Canada Accepts Seattle Genetics' (SGEN) ADCETRIS NDS for REview
May 23, 9:04AM Street Insider
May 23, 9:04AM Street Insider
Seattle Genetics Announces Health Canada Accepts ADCETRIS® New Drug Submission for Review
May 23, 9:00AM Business Wire
May 23, 9:00AM Business Wire
$SGEN anyone know why all the wild swings on this one? have not traded it in 6 months or more but don't see recent news.
about 12 days ago by Good2go
about 12 days ago by Good2go
UBS Raises PT on Seattle Genetics (SGEN) on Adcetris Label Expansion Opportunities
May 18, 1:48PM Street Insider
May 18, 1:48PM Street Insider
Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting
May 16, 6:08PM Business Wire
May 16, 6:08PM Business Wire
THE GOOD LEADS http://stks.co/3o6C starring @newsfromIN @chessnwine @emergingmoney @michaelkitces @bespokeinvest $CMG $SGEN $JPM
about 18 days ago by reformedbroker
about 18 days ago by reformedbroker
Seattle Genetics to Present at Bank of America Merrill Lynch Health Care Conference
May 11, 9:00AM Business Wire
May 11, 9:00AM Business Wire
Seattle Genetics Announces Data from Investigator Trial of ADCETRIS™ in Relapsed Cutaneous T-Cell Lymphoma
May 10, 10:00AM Business Wire
May 10, 10:00AM Business Wire
Leerink Swann Maintains an 'Outperform' on Seattle Genetics (SGEN); Modest Growth, but Opportunities in Pipeline
May 09, 12:49PM Street Insider
May 09, 12:49PM Street Insider
Quant modell indicates a 2 - 1 chance for $SGEN not closing above 19.40 today. Now trading at 19.19 or +0.8%
about 23 days ago by TradeBot
about 23 days ago by TradeBot
$SGEN 200 Day SMA Cross - Price crossed above 200 day SMA (18.1086). Confirmed by volume.
about 23 days ago by TradeIdeasQuant
about 23 days ago by TradeIdeasQuant
Listen to $SGEN Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3jHj
about 24 days ago by earningscast
about 24 days ago by earningscast
Seattle Genetics (SGEN), Takeda's Millennium Announce Deal with Ventana on Companion Diagnostic for ADCETRIS
Apr 12, 9:04AM Street Insider
Apr 12, 9:04AM Street Insider
Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACR
Apr 03, 2:00PM Business Wire
Apr 03, 2:00PM Business Wire
Seattle Genetics (SGEN) Announces Pivotal ADCETRIS Study Published in JCO
Mar 26, 4:04PM Street Insider
Mar 26, 4:04PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SGEN | 19.11 | -0.37 | -1.90% | 2.267B |
| SGC | 11.74 | -0.13 | -1.10% | 70.56M |
| SGA | 34.15 | -0.75 | -2.15% | 148.32M |
| SFY | 18.11 | -1.80 | -9.04% | 846.97M |
| SFUN | 14.93 | -0.85 | -5.39% | 801.15M |
| SFSF | 39.99 | +0.00 | +0.00% | 3.392B |
| SFLY | 25.55 | -2.02 | -7.33% | 961.09M |
| SFL | 15.19 | -0.30 | -1.94% | 1.226B |
| SEH | 3.70 | -0.06 | -1.60% | 115.88M |
| SEED | 1.565 | -0.14 | -7.94% | 39.75M |
